Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $5.0M
- Enterprise value
- $5.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $1.05
- 52-wk low
- $0.25
- Beta
- —
- Shares out
- 7.2M
5-year trend
What this company does
BUSINESS Business Overview We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies. Business Strategy Our strategy is to leverage our considerable industry experience, understanding of immunotherapies, and development expertise to identify, develop and commercialize product candidates with significant market potential that can fulfill unmet medical needs in the treatment of cancer. We have assembled a…
AI summary unavailable — showing raw filing excerpt
Generated from CPMV's filing dated 2026-04-15
Key risks
RISK FACTORS Investing in our common stock is speculative and illiquid and involves a high degree of risk including the risk of a loss of your entire investment. You should carefully consider the risks and uncertainties described below and the other information contained in this Annual Report on Form 10-K (“Report”) before investing in our common stock. The risks set forth below are not the only ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and prospects. If any of the following risks actually materialize, our business, financial condition, prospects and/or operations could suffer. In such event, the value of our…
AI summary unavailable — showing raw filing excerpt
Generated from CPMV's filing dated 2026-04-15
Profitability
Return on equity
9.2%
32.3%Return on assets
-3459.6%
431.4%Leverage
Debt / equity
-1.00×
1.8%Debt / assets
37702.0%
670.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-175.4K | +3.3% | — |
Q4 2025 2025-12-31 | — | — | $-169.1K | -10.5% | — |
Q3 2025 2025-09-30 | — | — | $-165.4K | +11.4% | — |
Q2 2025 2025-06-30 | — | — | $-172.0K | +41.4% | — |
Q1 2025 2025-03-31 | — | — | $-181.3K | +37.1% | — |
Q4 2024 2024-12-31 | — | — | $-153.0K | — | — |
Q3 2024 2024-09-30 | — | — | $-186.7K | +44.0% | — |
Q2 2024 2024-06-30 | — | — | $-293.7K | -1597.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on CPMV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for CPMV in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns CPMV
Institutional value
$0
Total shares held
1
Distinct holders
1
+0 vs prior
As of
2025-09-30
Prior: 2025-06-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | West Oak Capital, LLC | 1 | $0 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CPMV's latest filing finishes processing.